Effects of Growth Hormone–Releasing Factor in HIV-Infected Patients  

Oleh:

Pimpinella, Giuseppe (Editor); Malgarini, Renato Bertini (Editor)

Jenis: Article from Journal - ilmiah internasional
Dalam koleksi: The New England Journal of Medicine (keterangan: ada di Proquest) vol. 358 no. 09 (Feb. 2008), page 969.

Ketersediaan

Perpustakaan FK Nomor Panggil: N08.K.2008.01 Non-tandon: 1 (dapat dipinjam: 0) Tandon: tidak ada

Lihat Detail Induk

Isi artikel

To the Editor: In their article on the effects of growth hormone–releasing factor in patients with human immunodeficiency virus (HIV) infection, Falutz and colleagues (Dec. 6 issue)1 state that tesamorelin, a synthetic growth hormone–releasing factor, might be useful in the treatment of lipodystrophy related to antiretroviral drugs. However, the primary end point of the trial was the reduction of visceral adipose tissue as assessed by computed tomographic scanning; the study was not designed to detect a reduction in cardiovascular risk. These results came after the decision by the Food and Drug Administration (FDA) not to grant as an indication for . . .

Opini Anda

Klik untuk menuliskan opini Anda tentang koleksi ini!

Kembali